Q2 2025 Amgen Inc Earnings Call Transcript
Key Points
- Amgen Inc (AMGN) reported a 9% year-over-year revenue growth in Q2 2025, driven by a 13% increase in volume.
- Fifteen products delivered double-digit sales growth, showcasing the strength and diversity of Amgen Inc (AMGN)'s portfolio.
- The company is advancing a robust pipeline with multiple Phase 3 readouts in the first half of 2025, indicating strong future growth potential.
- Amgen Inc (AMGN) is leveraging AI to enhance innovation and productivity across its operations, from discovery to commercial execution.
- The biosimilars portfolio grew 40% year-over-year, contributing significantly to top-line growth and generating meaningful cash flows.
- Net selling prices for medicines are declining across the industry, which could impact future revenue growth.
- Prolia sales declined 4% year-over-year due to lower net selling prices and competition from biosimilars.
- The company faces ongoing challenges related to pricing and tariffs, which could affect profitability.
- Amgen Inc (AMGN) is experiencing increased non-GAAP R&D expenses, which rose 18% year-over-year, impacting operating margins.
- The company anticipates fluctuations in sales for certain products, such as WEZLANA and AMGEVITA, which could lead to revenue volatility.
My name is Julianne, and I will be your conference facilitator today for the Amgen Q2 FY 2025 earnings conference call. (Operator Instructions)
I would now like to introduce Justin Claeys, Vice President of Investor Relations. Mr. Claeys, you may now begin
Good afternoon, everyone, and welcome to our second quarter 2025 earnings call. Bob Bradway will lead the call and be followed by a broader review of our performance by Murdo Gordon, Jay Bradner and Peter Griffith. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements which are qualified by our safe harbor statement, and please note that actual results could vary materially.
Over to you, Bob.
Good
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
